Boltwood Capital Management trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 66.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,722 shares of the conglomerate’s stock after selling 15,417 shares during the quarter. Boltwood Capital Management’s holdings in Danaher were worth $716,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. ETRADE Capital Management LLC increased its holdings in Danaher by 5.1% in the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after buying an additional 917 shares during the period. Honeywell International Inc. bought a new position in Danaher in the 2nd quarter valued at about $25,317,000. Roundview Capital LLC increased its holdings in Danaher by 2.0% in the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after buying an additional 502 shares during the period. Veritable L.P. increased its holdings in Danaher by 28.2% in the 2nd quarter. Veritable L.P. now owns 40,486 shares of the conglomerate’s stock valued at $3,417,000 after buying an additional 8,912 shares during the period. Finally, Wealthfront Inc. increased its holdings in Danaher by 10.2% in the 2nd quarter. Wealthfront Inc. now owns 14,574 shares of the conglomerate’s stock valued at $1,230,000 after buying an additional 1,348 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.
Shares of Danaher Co. (NYSE DHR) opened at $98.61 on Wednesday. Danaher Co. has a one year low of $78.97 and a one year high of $98.88. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The firm has a market cap of $68,130.00, a P/E ratio of 29.35, a PEG ratio of 2.07 and a beta of 1.03.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a $0.14 dividend. The ex-dividend date is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.57%. Danaher’s payout ratio is currently 16.67%.
In related news, CFO Daniel L. Comas sold 88,184 shares of Danaher stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.02, for a total transaction of $8,026,507.68. Following the sale, the chief financial officer now directly owns 227,816 shares in the company, valued at approximately $20,735,812.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of Danaher stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the sale, the chief executive officer now owns 271,737 shares in the company, valued at $25,173,715.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is currently owned by corporate insiders.
Several equities analysts have commented on DHR shares. Morgan Stanley raised their target price on shares of Danaher from $95.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 20th. Credit Suisse Group raised their target price on shares of Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a report on Thursday, October 5th. Goldman Sachs Group reissued a “neutral” rating and issued a $83.00 target price on shares of Danaher in a report on Tuesday, September 26th. Finally, Citigroup raised their target price on shares of Danaher to $107.00 and gave the company a “buy” rating in a report on Friday, December 15th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $94.91.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.